Uncategorized
Ohr enrolls first patient in phase 3 clinical trial of squalamine for wet AMD
Ohr Pharmaceutical has enrolled the first patient in the first of two phase 3 clinical trials of squalamine lactate ophthalmic solution 0.2% for the treatment of neovascular age-related macular degeneration, according to a press release. The phase 3 clinical program will include two randomized, double-masked, placebo-controlled trials of squalamine (OHR-102). The first trial has a target enrollment of 650 patients who are newly diagnosed wet AMD and will be administered OHR-102 in combination with Lucentis (ranibizumab, Genentech) twice a day.